Business Context and Reporting Period
This Form 8-K is a current report filed by Bone Biologics Corporation (BBLG) on May 23, 2022. The filing addresses corporate governance matters, specifically the scheduling of the 2022 Annual Meeting of Stockholders and the establishment of deadlines for shareholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance notifications and does not contain financial performance data.
Material Changes
The primary material change disclosed is the formal announcement of the 2022 Annual Meeting of Stockholders, scheduled for August 23, 2022. The record date for determining stockholders entitled to vote is set for June 24, 2022. The filing notes that because the Company did not hold a 2021 Annual Meeting, standard deadlines for stockholder proposals under Rule 14a-8 are no longer applicable, necessitating the revised deadlines provided in this report.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies are disclosed in this document. The only unusual item noted is the absence of a 2021 Annual Meeting, which altered the procedural timeline for the 2022 meeting.
Key Facts for Investors to Verify
- Annual Meeting Date: August 23, 2022.
- Record Date: June 24, 2022 (close of business).
- Proposal Deadline: June 23, 2022 (close of business) for inclusion in proxy materials.
- Submission Address: Corporate Secretary, Bone Biologics Corporation, 2 Burlington Woods Drive, Ste. 100, Burlington, MA 01803.
- Securities Traded: Common stock (BBLG) and Warrants (BBLGW) on The Nasdaq Stock Market LLC.